Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Eureka Community Hospital
mi
from
Eureka, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Eureka Community Hospital
mi
from
Eureka, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Galesburg Clinic, PC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Mason District Hospital
mi
from
Havana, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Mason District Hospital
mi
from
Havana, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Hopedale Medical Complex
mi
from
Hopedale, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Hopedale Medical Complex
mi
from
Hopedale, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
McDonough District Hospital
mi
from
Macomb, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
McDonough District Hospital
mi
from
Macomb, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
BroMenn Regional Medical Center
mi
from
Normal, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Community Cancer Center
mi
from
Normal, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Community Cancer Center
mi
from
Normal, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
OSF Saint Elizabeth Medical Center
mi
from
Ottawa, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
OSF Saint Elizabeth Medical Center
mi
from
Ottawa, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Oncology Hematology Associates of Central Illinois, PC - Ottawa
mi
from
Ottawa, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Oncology Hematology Associates of Central Illinois, PC - Ottawa
mi
from
Ottawa, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Cancer Treatment Center at Pekin Hospital
mi
from
Pekin, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Cancer Treatment Center at Pekin Hospital
mi
from
Pekin, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Proctor Hospital
mi
from
Peoria, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Proctor Hospital
mi
from
Peoria, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
CCOP - Illinois Oncology Research Association
mi
from
Peoria, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Oncology Hematology Associates of Central Illinois, PC - Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
OSF St. Francis Medical Center
mi
from
Peoria, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
OSF St. Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Illinois Valley Community Hospital
mi
from
Peru, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Illinois Valley Community Hospital
mi
from
Peru, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Perry Memorial Hospital
mi
from
Princeton, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Perry Memorial Hospital
mi
from
Princeton, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
St. Margaret's Hospital
mi
from
Spring Valley, IL
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
St. Margaret's Hospital
mi
from
Spring Valley, IL
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Elkhart General Hospital
mi
from
Elkhart, IN
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Elkhart General Hospital
mi
from
Elkhart, IN
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Howard Community Hospital
mi
from
Kokomo, IN
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Howard Community Hospital
mi
from
Kokomo, IN
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Center for Cancer Therapy at LaPorte Hospital and Health Services
mi
from
La Porte, IN
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Center for Cancer Therapy at LaPorte Hospital and Health Services
mi
from
La Porte, IN
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
CCOP - Northern Indiana CR Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Memorial Hospital of South Bend
mi
from
South Bend, IN
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Memorial Hospital of South Bend
mi
from
South Bend, IN
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Saint Joseph Regional Medical Center
mi
from
South Bend, IN
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Saint Joseph Regional Medical Center
mi
from
South Bend, IN
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
South Bend Clinic
mi
from
South Bend, IN
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
South Bend Clinic
mi
from
South Bend, IN
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
CancerCare of Maine at Eastern Maine Medical Center
mi
from
Bangor, ME
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
CancerCare of Maine at Eastern Maine Medical Center
mi
from
Bangor, ME
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Union Hospital Cancer Program at Union Hospital
mi
from
Elkton MD, MD
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Union Hospital Cancer Program at Union Hospital
mi
from
Elkton MD, MD
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
St. Joseph, MI
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Lakeland Regional Cancer Care Center - St. Joseph
mi
from
St. Joseph, MI
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Cancer Resource Center - Lincoln
mi
from
Lincoln, NE
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Cancer Resource Center - Lincoln
mi
from
Lincoln, NE
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
CCOP - Missouri Valley Cancer Consortium
mi
from
Omaha, NE
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Immanuel Medical Center
mi
from
Omaha, NE
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Immanuel Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Alegent Health Cancer Center at Bergan Mercy Medical Center
mi
from
Omaha, NE
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Alegent Health Cancer Center at Bergan Mercy Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Creighton University Medical Center
mi
from
Omaha, NE
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Creighton University Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Mount Sinai Hospital
mi
from
New York, NY
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Randolph Hospital
mi
from
Asheboro, NC
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Randolph Hospital
mi
from
Asheboro, NC
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
mi
from
Greensboro, NC
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
mi
from
Greensboro, NC
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Kinston Medical Specialists
mi
from
Kinston, NC
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Kinston Medical Specialists
mi
from
Kinston, NC
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Annie Penn Cancer Center
mi
from
Reidsville, NC
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Annie Penn Cancer Center
mi
from
Reidsville, NC
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Danville Regional Medical Center
mi
from
Danville, VA
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Danville Regional Medical Center
mi
from
Danville, VA
Click here to add this to my saved trials
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated:  11/23/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
A Phase II Study of Galiximab (Anti-CD80) for Patients With Relapsed/Refractory Hodgkin Lymphoma
Status: Enrolling
Updated: 11/23/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22 Monoclonal Antibody) (CALGB IND #XXXXX) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated:  11/23/2015
Kaiser Permanente Medical Office -Vandever Medical Office
mi
from
San Diego, CA
Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
A Phase II Trial of Extended Induction Epratuzumab (Anti-CD22 Monoclonal Antibody) (CALGB IND #XXXXX) Plus Rituximab in Previously Untreated Follicular Non-Hodgkin's Lymphoma (NHL)
Status: Enrolling
Updated: 11/23/2015
Kaiser Permanente Medical Office -Vandever Medical Office
mi
from
San Diego, CA
Click here to add this to my saved trials